Apellis Pharmaceuticals Target Price
| APLS Stock | USD 23.49 0.93 4.12% |
As of the 9th of February, Apellis Pharmaceuticals shows the mean deviation of 2.5, and Risk Adjusted Performance of 0.066. Apellis Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Apellis Pharmaceuticals standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Apellis Pharmaceuticals is priced correctly, providing market reflects its regular price of 23.49 per share. Given that Apellis Pharmaceuticals has jensen alpha of 0.1895, we suggest you to validate Apellis Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.
Apellis Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.9167 | Revenue |
Apellis | Target Price | Build AI portfolio with Apellis Stock |
Apellis Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Apellis Pharmaceuticals' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Apellis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Apellis Pharmaceuticals by comparing valuation metrics of similar companies.Apellis Pharmaceuticals is currently under evaluation in target price category among its peers.
Apellis Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Apellis Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Apellis Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Apellis Fundamentals
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0513 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.49 % | ||||
| Current Valuation | 2.96 B | ||||
| Shares Outstanding | 126.53 M | ||||
| Shares Owned By Insiders | 13.92 % | ||||
| Shares Owned By Institutions | 86.08 % | ||||
| Number Of Shares Shorted | 18.11 M | ||||
| Price To Earning | (6.94) X | ||||
| Price To Book | 7.40 X | ||||
| Price To Sales | 2.92 X | ||||
| Revenue | 781.37 M | ||||
| Gross Profit | 605.05 M | ||||
| EBITDA | (154.53 M) | ||||
| Net Income | (197.88 M) | ||||
| Cash And Equivalents | 852.8 M | ||||
| Cash Per Share | 7.76 X | ||||
| Total Debt | 469.78 M | ||||
| Debt To Equity | 0.63 % | ||||
| Current Ratio | 7.57 X | ||||
| Book Value Per Share | 3.17 X | ||||
| Cash Flow From Operations | (87.87 M) | ||||
| Short Ratio | 6.39 X | ||||
| Earnings Per Share | 0.36 X | ||||
| Price To Earnings To Growth | (0.30) X | ||||
| Target Price | 33.95 | ||||
| Number Of Employees | 705 | ||||
| Beta | 0.24 | ||||
| Market Capitalization | 2.97 B | ||||
| Total Asset | 885.05 M | ||||
| Retained Earnings | (3.04 B) | ||||
| Working Capital | 603.45 M | ||||
| Current Asset | 115.82 M | ||||
| Current Liabilities | 5.13 M | ||||
| Net Asset | 885.05 M |
About Apellis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apellis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.